Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: Clinical evidence and possible underlying mechanisms

American Heart Journal

Volumn 154, Issue 2, 2007, Pages 391-402

  Merla, Ramanna ^a   Daher, Iyad N ^a   Ye, Yumei ^a   Uretsky, Barry F ^a   Birnbaum, Yochai ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ECTO 5' NUCLEOTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MEVINOLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRAVASTATIN; PROSTAGLANDIN; PROTEIN KINASE B; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG MECHANISM; HEART INFARCTION SIZE; HEART SURGERY; HUMAN; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; SURGICAL PROCEDURES, OPERATIVE;

EID: 34447571672     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.04.029     Document Type: Review

References (85)

1. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
2. Hausenloy D.J., and Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61 (2004) 448-460
3. Sanada S., and Kitakaze M. Ischemic preconditioning: emerging evidence, controversy, and translational trials. Int J Cardiol 97 (2004) 263-276
4. Bell R.M., and Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41 (2003) 508-515
5. Efthymiou C.A., Mocanu M.M., and Yellon D.M. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45 (2005) 247-252
6. Wolfrum S., Dendorfer A., Schutt M., et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44 (2004) 348-355
7. Sanada S., Asanuma H., Minamino T., et al. Optimal windows of statin use for immediate infarct limitation: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 110 (2004) 2143-2149
8. Tiefenbacher C.P., Kapitza J., Dietz V., et al. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 285 (2003) H59-H64
9. Lindenauer P.K., Pekow P., Wang K., et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291 (2004) 2092-2099
10. Poldermans D., Bax J.J., Kertai M.D., et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107 (2003) 1848-1851
11. Ward R.P., Leeper N.J., Kirkpatrick J.N., et al. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 104 (2005) 264-268
12. Kertai M.D., Boersma E., Westerhout C.M., et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 116 (2004) 96-103
13. O'Neil-Callahan K., Katsimaglis G., Tepper M.R., et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 45 (2005) 336-342
14. Durazzo A.E., Machado F.S., Ikeoka D.T., et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 39 (2004) 967-975 [discussion 975-6]
15. Dotani MI, Elnicki DM, Jain AC, et al., Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000;86:1128-30, A6.
16. Pan W., Pintar T., Anton J., et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 110 (2004) II45-II49
17. Pascual D.A., Arribas J.M., Tornel P.L., et al. Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. Ann Thorac Surg 81 (2006) 78-83
18. Herrmann J., Lerman A., Baumgart D., et al. Preprocedural statin medication reduces the extent of periprocedural non-Q wave myocardial infarction. Circulation 106 (2002) 2180-2183
19. Chan A.W., Bhatt D.L., Chew D.P., et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105 (2002) 691-696
20. Chan A.W., Bhatt D.L., Chew D.P., et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 107 (2003) 1750-1756
21. Chang S.M., Yazbek N., and Lakkis N.M. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 62 (2004) 193-197
22. Mulukutla S.R., Marroquin O.C., Smith C., et al. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. Am J Cardiol 94 (2004) 1363-1366
23. Briguori C., Colombo A., Airoldi F., et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 25 (2004) 1822-1828
24. Pasceri V., Patti G., Nusca A., et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110 (2004) 674-678
25. Mangano D.T. Perioperative cardiac morbidity. Anesthesiology 72 (1990) 153-184
26. Badner N.H., Knill R.L., Brown J.E., et al. Myocardial infarction after noncardiac surgery. Anesthesiology 88 (1998) 572-578
27. Devereaux P.J., Goldman L., Cook D.J., et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 173 (2005) 627-634
28. Goldman L., Caldera D.L., Nussbaum S.R., et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 297 (1977) 845-850
29. Detsky A.S., Abrams H.B., Forbath N., et al. Cardiac assessment for patients undergoing noncardiac surgery. A multifactorial clinical risk index. Arch Intern Med 146 (1986) 2131-2134
30. Eagle K.A., Berger P.B., Calkins H., et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 105 (2002) 1257-1267
31. Birjiniuk V. Patient outcomes in the assessment of myocardial injury following cardiac surgery. Ann Thorac Surg 72 (2001) S2208-S2212 [discussion S2212-3, S2267-70]
32. Ashton C.M., Petersen N.J., Wray N.P., et al. The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Ann Intern Med 118 (1993) 504-510
33. Fleisher L.A., Beckman J.A., Brown K.A., et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. Circulation 113 (2006) 2662-2674
34. Schouten O., Kertai M.D., Bax J.J., et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 95 (2005) 658-660
35. Kennedy J., Quan H., Buchan A.M., et al. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 36 (2005) 2072-2076
36. McGirt M.J., Perler B.A., Brooke B.S., et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 42 (2005) 829-836 [discussion 836-7]
37. Feringa H.H., Bax J.J., Schouten O., et al. Protecting the heart with cardiac medication in patients with left ventricular dysfunction undergoing major noncardiac vascular surgery. Semin Cardiothorac Vasc Anesth 10 (2006) 25-31
38. Noordzij P.G., Poldermans D., Schouten O., et al. Beta-blockers and statins are individually associated with reduced mortality in patients undergoing noncardiac, nonvascular surgery. Coron Artery Dis 18 (2007) 67-72
39. Amar D., Zhang H., Heerdt P.M., et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 128 (2005) 3421-3427
40. Abbruzzese T.A., Havens J., Belkin M., et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 39 (2004) 1178-1185
41. Ali I.S., and Buth K.J. Preoperative statin use and in-hospital outcomes following heart surgery in patients with unstable angina. Eur J Cardiothorac Surg 27 (2005) 1051-1056
42. Collard C.D., Body S.C., Shernan S.K., et al. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 132 (2006) 392-400
43. Kapoor A.S., Kanji H., Buckingham J., et al. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. BMJ 333 (2006) 1149
44. Grimes D.A., and Schulz K.F. Bias and causal associations in observational research. Lancet 359 (2002) 248-252
45. Califf R.M., Abdelmeguid A.E., Kuntz R.E., et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 31 (1998) 241-251
46. Mahmarian J.J., Pratt C.M., Borges-Neto S., et al. Quantification of infarct size by 201Tl single-photon emission computed tomography during acute myocardial infarction in humans. Comparison with enzymatic estimates. Circulation 78 (1988) 831-839
47. Turer A.T., Mahaffey K.W., Gallup D., et al. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials, Cardiovasc Med 6 (2005) 12
48. Ellis S.G., Chew D., Chan A., et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 106 (2002) 1205-1210
49. Singh M., Lennon R.J., Roger V.L., et al. Relation of preprocedural statin therapy to in-hospital procedural complications following percutaneous coronary interventions in patients with hyperlipidemia. Am J Cardiol 98 (2006) 325-330
50. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49 (2007) 1272-1278
51. Lefer D.J. Statins as potent antiinflammatory drugs. Circulation 106 (2002) 2041-2042
52. Sanguigni V., Pignatelli P., Lenti L., et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111 (2005) 412-419
53. Yokoyama S., Ikeda H., Haramaki N., et al. HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats. J Cardiovasc Pharmacol 45 (2005) 375-381
54. Thompson P.D., Moyna N.M., White C.M., et al. The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis 161 (2002) 301-306
55. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
56. Nissen S.E. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 96 (2005) 61F-68F
57. Birnbaum Y., Ye Y., Rosanio S., et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 65 (2005) 345-355
58. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 (1998) 24266-24271
59. Kozai T., Eto M., Yang Z., et al. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway. Cardiovasc Res 68 (2005) 475-482
60. Ming X.F., Viswambharan H., Barandier C., et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22 (2002) 8467-8477
61. Eto M., Kozai T., Cosentino F., et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105 (2002) 1756-1759
62. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
63. Bergmann M.W., Rechner C., Freund C., et al. Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3beta and transcription factor beta-catenin. J Mol Cell Cardiol 37 (2004) 681-690
64. Rattan R., Giri S., Singh A.K., et al. Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKalpha. Free Radic Biol Med 35 (2003) 1037-1050
65. Degraeve F., Bolla M., Blaie S., et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 276 (2001) 46849-46855
66. Birnbaum Y., Ashitkov T., Uretsky B.F., et al. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther 17 (2003) 25-30
67. Atar S., Ye Y., Lin Y., et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 290 (2006) H1960-H1968
68. Rosanio S., Ye Y., Atar S., et al. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 20 (2006) 27-36
69. Harris M.B., Blackstone M.A., Sood S.G., et al. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287 (2004) H560-H566
70. Ye Y., Lin Y., Atar S., et al. Myocardial protection by pioglitazone, atorvastatin and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol (2006) H1158-H1159
71. Wolfrum S., Grimm M., Heidbreder M., et al. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol 41 (2003) 474-480
72. Laufs U., Gertz K., Dirnagl U., et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942 (2002) 23-30
73. Di Napoli P., Antonio Taccardi A., Grilli A., et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 51 (2001) 283-293
74. Wang J., Tokoro T., Matsui K., et al. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci 76 (2005) 2257-2268
75. Feron O., Dessy C., Desager J.P., et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103 (2001) 113-118
76. Brouet A., Sonveaux P., Dessy C., et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89 (2001) 866-873
77. Birnbaum Y., Ye Y., Atar S., et al. The increased expression of cyclooxygenase-2 by atorvastatin is iNOS-dependent, but eNOS and NFkB-independent. Arterioscler Thromb Vasc Biol 26 (2006) e44
78. Scalia R., Gooszen M.E., Jones S.P., et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103 (2001) 2598-2603
79. Birnbaum Y., Ye Y., Lin Y., et al. Mechanism of myocardial protection by atorvastatin: 5′-nucleotidase is upstream of eNOS activation. Circ Res 99 (2006) E26
80. Birnbaum Y., Lin Y., Ye Y., et al. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol (2007) Feb 2; [Epub ahead of print]
81. Lascano E.C., Del Valle H.F., and Negroni J.A. Effect of different doses of aspirin on preconditioning against stunning in conscious sheep. Medicina (B Aires) 64 (2004) 30-36
82. Ueda Y., Kitakaze M., Komamura K., et al. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 34 (1999) 2120-2125
83. Cunha R.A. Regulation of the ecto-nucleotidase pathway in rat hippocampal nerve terminals. Neurochem Res 26 (2001) 979-991
84. Lee T.M., Su S.F., Chou T.F., et al. Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine. Am J Cardiol 88 (2001) 1108-1113
85. Ye Y., Lin Y., Perez-Polo J.R., et al. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol (2007) Apr 6; [Epub ahead of print]